AIT 102
Alternative Names: AIT-102; EC-8042; Mithramycin-analogue - OrphAI TherapeuticsLatest Information Update: 28 Jan 2025
At a glance
- Originator EntreChem
- Developer EntreChem; OrphAI Therapeutics
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
- Mechanism of Action Apoptosis stimulants; Sp1 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Rhabdoid tumour
- No development reported Ewing's sarcoma
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Ewing's Sarcoma in USA (Intraperitoneal)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Ewing's Sarcoma in USA (IV)
- 28 Sep 2023 AI Therapeutics is now called OrphAI Therapeutics